Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790973 | 0.80 | CYP11B2 (0.43) | HTR6MAP4K1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18790971 | 0.78 | CYP11B2 (0.44) | HTR6MAP4K1CYP3A4KCNH2 | |
| SCHEMBL18791103 | 0.72 | HTR7 (0.58) | HTR6ACVR1CYP3A4CYP2C19 | |
| SCHEMBL8858015 | 0.72 | ADRB1 (0.61) | TGFBR1 | |
| SCHEMBL18790967 | 0.71 | ERN1 (0.43) | MAP4K1KCNH2 | |
| SCHEMBL18790965 | 0.71 | CYP11B2 (0.38) | MAP4K1KCNH2 | |
| SCHEMBL14982162 | 0.71 | ADRB1 (0.51) | TGFBR1HTR6ACVR1 | |
| SCHEMBL2334070 | 0.70 | GRIA1 (0.40) | HTR6 | |
| SCHEMBL18791036 | 0.70 | HTR7 (0.56) | HTR6NMT1CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL3320427 | 0.69 | GRIA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| WO-2017069226-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | REN, NR3C2, NR5A1 | TGFBR1 1219/4885HTR6 3390/4885MAP4K1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.